Huntington’s Disease (HD) Research: Key Targets and Antibody Tools

Huntington’s disease (HD) was first systematically described in 1872 by the American physician George Huntington, after whom the condition is named. It is a fully penetrant autosomal dominant neurodegenerative disorder — inheriting just one mutant allele is sufficient to cause disease. A hallmark feature is genetic anticipation, where successive generations typically develop symptoms earlier than their parents. Global prevalence is approximately 5–10 per 100,000, with slightly lower rates in East Asian populations, though diagnostic awareness has risen sharply in recent years. Classic symptoms include uncontrollable choreiform movements, psychiatric disturbances, and progressive cognitive decline. Onset is usually between 30 and 50 years of age, with a disease course of 10–25 years ending in complications such as dysphagia, pneumonia, or cardiac failure.

The root cause of HD is an abnormal expansion of CAG trinucleotide repeats in exon 1 of the HTT gene ; 36–39 repeats show reduced penetrance; and ≥40 repeats are almost fully penetrant. The expanded CAG tract encodes an abnormally long polyglutamine (polyQ) stretch at the N-terminus of Huntingtin, conferring toxic gain-of-function: misfolding and aggregation, transcriptional dysregulation, impaired axonal transport, blocked autophagy clearance, and suppressed BDNF production/transport. These events culminate in selective loss of medium spiny neurons (MSNs) in the striatum and cortical neurons.

                          Fig 1.Schematic of diverging pathways leading to the pathogenesis of HD(doi.org/10.3390/brainsci12101389）

Key Targets in Huntington’s Disease Research

Although HD is caused by a single-gene mutation, its downstream pathology is extraordinarily complex, involving protein homeostasis, neurotrophic support, autophagy, excitotoxicity, and mitochondrial dysfunction. The table below summarizes the most widely accepted core targets and their roles in HD, providing a foundation for therapeutic intervention.

 Latest Research Progress

The table below summarizes major clinical and basic research advances in HD from leading journals, trial registries, and authoritative sources.

abinScience Huntington’s Disease Research Recombinant Proteins and Antibodies

Below are abinScience’s latest recombinant proteins and antibodies targeting core HD pathways. Catalog numbers link directly to product pages.